Efficacy and Prognostic Indicators of Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) in Daratumumab-Refractory Multiple Myeloma Patients: A Multicenter Real-World Study.
Long-Term Survival with Multiple Myeloma: An Italian Experience
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma.
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.
The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice?
Correction: Mancuso et al. Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma. <i>Cancers</i> 2025, <i>17</i>, 1168.
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study.
Long-Term Survival with Multiple Myeloma: An Italian Experience.
Infection Events in Patients With Newly Diagnosed Multiple Myeloma With Anti-cd38 Monoclonal Antibody-based First Line Regimens: A Multicentric Italian Experience
Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended follow-up of a multicenter, retrospective real-world experience with 321 cases outside of controlled clinical trials.
The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management.
Belantamab mafodotin in triple-refractory multiple myeloma patients: A retro-prospective observational study in Italy.
Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment.
Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences.
Real-world assessment of treatment patterns and outcomes in patients with relapsed-refractory multiple myeloma in an Italian haematological tertiary care centre.
Current Main Topics in Multiple Myeloma.
Maintenance therapy in multiple myeloma: Two is not always better than one.
P36 BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT AND ONE ANTI-CD38 MONOCLONAL ANTIBODY: A RETRO-PROSPECTIVE ITALIAN OBSERVATIONAL STUDY
Belantamab Mafodotin: From Clinical Trials Data to Real Life Experiences
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial
Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study
Autologous Stem Cell Transplantation in Multiple Myeloma: Where Are We and Where Do We Want to Go?
Association of IMWG frailty score with health-related quality of life profile of patients with relapsed refractory multiple myeloma in Italy and the UK: a GIMEMA, multicentre, cross-sectional study
Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study
Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
Consolidation and Maintenance in Newly Diagnosed Multiple Myeloma.
Novel Experimental Drugs for Treatment of Multiple Myeloma.
The Accuracy of the International Myeloma Working Group Frailty Score in Capturing Health-Related Quality of Life Profile of Patients with Relapsed Refractory Multiple Myeloma
Anticoagulation and Vessel Recanalization in Cirrhotic Patients with Splanchnic Vein Thrombosis: A Multidisciplinary "Real Life" Experience.
Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents